[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 26, Issue 5 (Bimonthly 2022) ::
Feyz 2022, 26(5): 605-616 Back to browse issues page
Metabolic dysfunction-associated fatty liver disease and metabolic-associated steatohepatitis: a review of pathogenesis and potential pharmacological targets
Samaneh Olapour , Hamid Yaghooti *
Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, I.R Iran. , hmdyaghooti@gmail.com
Abstract:   (507 Views)
Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is one of the most common liver diseases that results from excess fat accumulation in the hepatocytes. The progression of steatosis to hepatocellular necrosis and inflammation leads to metabolic-associated steatohepatitis (MASH). Insulin resistance and obesity have significant roles in the disease process. Oxidative damage to hepatocytes and gut microflora dysbiosis may also contribute to the progression of fatty liver disease. There is currently no specific medication for MAFLD, and usually, lifestyle modifications are recommended. This study aimed to review the potential pharmacological targets for MAFLD.
Materials and Methods: In this paper, we studied the primary pharmacological targets for MAFLD and MASH, focusing on current evidence from clinical trials registered on the WHO International Clinical Trials Registry Platform (ICTRP) and published articles in PubMed, Google Scholar, ISI Web of Science, and Scopus databases.
Results: The peroxisome proliferator-activated receptors (PPARs), glucagon-like peptide-1 (GLP-1), farnesoid X receptor, statins, mediators of fibrosis and inflammation, weight loss agents, and probiotics were the primary targets in the treatment of fatty liver disease.
Conclusion: The drugs decreasing body weight, such as orlistat and GLP-1 analogs, have beneficial effects in obese patients with fatty liver disease. Moreover, insulin-sensitizers and lipid-lowering agents like PPAR agonists, GLP-1 analogs, and statins are valuable in this condition.
Keywords: Fatty liver disease, Steatohepatitis, Pathogenesis, Drug targets
Full-Text [PDF 704 kb]   (144 Downloads)    
Type of Study: Review | Subject: medicine, paraclinic
Received: 2022/06/13 | Accepted: 2022/09/18 | Published: 2022/12/4
1. Lee WM, Bae JH, Chang Y, Lee SH, Moon JE, Jeong SW, et al. Effect of Nutrition Education in NAFLD Patients Undergoing Simultaneous Hyperlipidemia Pharmacotherapy: A Randomized Controlled Trial. Nutrients 2021; 13(12): 4453.
2. Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metab Clin Exp 2017; 71(1): 17-32.
3. Yaghooti H, Ghanavati F, Seyedian SS, Cheraghian B, Mohammadtaghvaei N. The efficacy of calcitriol treatment in non-alcoholic fatty liver patients with different genotypes of vitamin D receptor FokI polymorphism. BMC Pharmacol Amp Toxicol 2021; 22(1): 1-9.
4. Matsubayashi Y, Fujihara K, Yamada-Harada M, Mitsuma Y, Sato T, Yaguchi Y, et al. Impact of metabolic syndrome and metabolic dysfunction-associated fatty liver disease on cardiovascular risk by the presence or absence of type 2 diabetes and according to sex. Cardiovasc Diabetol 2022; 21(1): 1-10.
5. Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, et al. Elafibranor, an agonist of the peroxisome proliferator− activated receptor− α and− δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 2016; 150(5): 1147-59.
6. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362(18):1675-85.
7. Lomonaco R, Ortiz‐Lopez C, Orsak B, Webb A, Hardies J, Darland C, et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology 2012; 55(5): 1389-97.
8. Magkos F, Su X, Bradley D, Fabbrini E, Conte C, Eagon JC, et al. Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects. Gastroenterology 2012; 142(7): 1444-6.
9. Akbari R, Yaghooti H, Jalali MT, Khorsandi LS, Mohammadtaghvaei N. Capparis spinosa improves the high fat diet-induced non-alcoholic steatohepatitis in rats: the possible role of FGF21. BMC Res Notes 2020; 13(1): 1-7.
10. Wu L, Sun J, Liu L, Du X, Liu Y, Yan X, et al. Anti-toll-like receptor 2 antibody ameliorates hepatic injury, inflammation, fibrosis and steatosis in obesity-related metabolic disorder rats via regulating MAPK and NF-κB pathways. Int Immunopharmacol 2020; 82(1): 106368.
11. Lefebvre E, Moyle G, Reshef R, Richman LP, Thompson M, Hong F, et al. Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis. PLoS One 2016; 11(6): e0158156.
12. Afarin R, Babaahmadi Rezaei H, Yaghooti H, Mohammadtaghvaei N. Fibroblast Growth Factor 21 Reduces Cholesterol-Induced Hepatic Fibrogenesis by Inhibiting TGF-β/Smad3C Signaling Pathway in LX2 Cells. Hepat Mon 2021; 21(4): e113321.
13. Ahn SB, Jun DW, Kang BK, Lim JH, Lim S, Chung M-J. Randomized, double-blind, placebo-controlled study of a multispecies probiotic mixture in nonalcoholic fatty liver disease. Sci Rep 2019; 9(1): 1-9.
14. Liang Y, Liang S, Zhang Y, Deng Y, He Y, Chen Y, et al. Oral administration of compound probiotics ameliorates HFD-induced gut microbe dysbiosis and chronic metabolic inflammation via the G protein-coupled receptor 43 in non-alcoholic fatty liver disease rats. Probiotics Antimicrob Proteins 2019; 11(1): 175-85.
15. Mohamad Nor MH, Ayob N, Mokhtar NM, Raja Ali RA, Tan GC, Wong Z, et al. The Effect of Probiotics (MCP® BCMC® Strains) on Hepatic Steatosis, Small Intestinal Mucosal Immune Function, and Intestinal Barrier in Patients with Non-Alcoholic Fatty Liver Disease. Nutrients 2021; 13(9): 3192.
16. López-Bautista F, Barbero-Becerra VJ, Ríos MY, Ramírez-Cisneros MÁ, Sánchez-Pérez CA, Ramos-Ostos MH, et al. Dietary consumption and serum pattern of bioactive fatty acids in NAFLD patients. Ann Hepatol 2020;19(5):482-8.
17. Boyraz M, Pirgon Ö, Dündar B, Çekmez F, Hatipoğlu N. Long-term treatment with n-3 polyunsaturated fatty acids as a monotherapy in children with nonalcoholic fatty liver disease. J Clin Res Pediatr Endocrinol 2015;7(2):121-7.
18. Zelber–Sagi S, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006;4(5):639-44.
19. Jensen VS, Hvid H, Damgaard J, Nygaard H, Ingvorsen C, Wulff EM, et al. Dietary fat stimulates development of NAFLD more potently than dietary fructose in Sprague–Dawley rats. Diabetol Metab Syndr 2018; 10(1): 1-13.
20. Oh S, So R, Shida T, Matsuo T, Kim B, Akiyama K, et al. High-intensity aerobic exercise improves both hepatic fat content and stiffness in sedentary obese men with nonalcoholic fatty liver disease. Sci Rep 2017; 7: 1-12.
21. Akbari R, Behdarvand T, Afarin R, Yaghooti H, Jalali MT, Mohammadtaghvaei N. Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis. BMC Pharmacol Toxicol 2021; 22(1): 1-9.
22. Hanf R, Millatt LJ, Cariou B, Noel B, Rigou G, Delataille P, et al. The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma–associated adverse cardiac effects. Diabetes Vasc Dis Res 2014; 11(6): 440-7.
23. Briand F, Maupoint J, Brousseau E, Breyner N, Bouchet M, Costard C, et al. Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters. Metab Clin Exp 2021; 117(1): 154707.
24. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010; 170(14): 1191-201.
25. Krishnappa M, Patil K, Parmar K, Trivedi P, Mody N, Shah C, et al. Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study). Cardiovasc Diabetol 2020; 19(1): 1-13.
26. Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, et al. Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial. Hepatology 2021; 74(4): 1809-24.
27. Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016; 387(10019): 679-90.
28. Li S, Wang X, Zhang J, Li J, Liu X, Ma Y, et al. Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease. Braz J Med Biol Res 2018; 51(8): e7299.
29. Kargiotis K, Athyros VG, Giouleme O, Katsiki N, Katsiki E, Anagnostis P, et al. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol 2015; 21(25): 7860-8.
30. Nascimbeni F, Aron-Wisnewsky J, Pais R, Tordjman J, Poitou C, Charlotte F, et al. Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. BMJ Open Gastroenterol 2016; 3(1): e000075.
31. Guo M, Zhao J, Zhai Y, Zang P, Lv Q, Shang D. A prospective study of hepatic safety of statins used in very elderly patients. BMC Geriatr 2019; 19(1): 1-7.
32. Hernandez ED, Zheng L, Kim Y, Fang B, Liu B, Valdez RA, et al. Tropifexor‐mediated abrogation of steatohepatitis and fibrosis is associated with the antioxidative gene expression profile in rodents. Hepatol Commun 2019; 3(8): 1085-97.
33. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015; 385(9972): 956-65.
34. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013; 145(3): 574-82.
35. Baniasadi N, Salajegheh F, Pardakhty A, Seyedmirzaee SM, Hayatbakhsh MM, Nikpoor AR, et al. Effects of pentoxifylline on non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled trial in Iran. Hepat Mon 2015; 15(11): e32418.
36. Koppe SW, Sahai A, Malladi P, Whitington PF, Green RM. Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. J Hepatol 2004; 41(4): 592-8.
37. Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo‐controlled trial. Hepatology 2011; 54(5): 1610-9.
38. Podszun MC, Alawad AS, Lingala S, Morris N, Huang W-CA, Yang S, et al. Vitamin E treatment in NAFLD patients demonstrates that oxidative stress drives steatosis through upregulation of de-novo lipogenesis. Redox biol 2020; 37(1): 101710.
39. Erhardt A, Stahl W, Sies H, Lirussi F, Donner A, Häussinger D. Plasma levels of vitamin E and carotenoids are decreased in patients with nonalcoholic steatohepatitis (NASH). Eur J Med Res 2011; 16(2): 76-8.
40. Barreyro FJ, Holod S, Finocchietto PV, Camino AM, Aquino JB, Avagnina A, et al. The pan‐caspase inhibitor Emricasan (IDN‐6556) decreases liver injury and fibrosis in a murine model of non‐alcoholic steatohepatitis. Liver Int 2015; 35(3): 953-66.
41. Pockros PJ, Schiff ER, Shiffman ML, McHutchison JG, Gish RG, Afdhal NH, et al. Oral IDN‐6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology 2007; 46(2): 324-9.
42. Shiffman M, Freilich B, Vuppalanchi R, Watt K, Burgess G, Morris M, et al. A placebo-controlled, multicenter, double-blind, randomised trial of emricasan in subjects with non-alcoholic fatty liver disease (NAFLD) and raised transaminases. J Hepatol 2015; 62: S282.
43. Harrison SA, Goodman Z, Jabbar A, Vemulapalli R, Younes ZH, Freilich B, et al. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. J Hepatol 2020; 72(5): 816-27.
44. Liang F, Giordano C, Shang D, Li Q, Petrof BJ. The dual CCR2/CCR5 chemokine receptor antagonist Cenicriviroc reduces macrophage infiltration and disease severity in Duchenne muscular dystrophy (Dmdmdx-4Cv) mice. PLoS One 2018; 13(3): e0194421.
45. Harrison SA, Fecht W, Brunt EM, Neuschwander‐Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 2009; 49(1): 80-6.
46. Ye J, Wu Y, Li F, Wu T, Shao C, Lin Y, et al. Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density fat fraction. Therap Adv Gastroenterol 2019; 12: 1756284819879047.
47. Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 2021; 384(12): 1113-24.
48. Bjarnason I, Sission G, Hayee BH. A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn’s disease. Inflammopharmacology 2019; 27(3): 465-73.
49. Javadi L, Ghavami M, Khoshbaten M, Safaiyan A, Barzegari A, Gargari BP. The potential role of probiotics or/and prebiotic on serum lipid profile and insulin resistance in alcoholic fatty liver disease: a double blind randomized clinical trial. Crescent J Med Biol Sci 2017; 4(3): 131-8.
50. Behrouz V, Aryaeian N, Zahedi MJ, Jazayeri S. Effects of probiotic and prebiotic supplementation on metabolic parameters, liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease. J Food Sci 2020; 85(10): 3611-7.
51. Chen CY, Tsen HY, Lin CL, Lin CK, Chuang LT, Chen CS, et al. Enhancement of the immune response against Salmonella infection of mice by heat-killed multispecies combinations of lactic acid bacteria. J Med Microbiol 2013; 62(11): 1657-64.
52. Aaron JG, Sobieszczyk ME, Weiner SD, Whittier S, Lowy FD, editors. Lactobacillus rhamnosus endocarditis after upper endoscopy. Open Forum Infect Dis 2017; 4(2): ofx085.
53. Vahabnezhad E, Mochon AB, Wozniak LJ, Ziring DA. Lactobacillus bacteremia associated with probiotic use in a pediatric patient with ulcerative colitis. J Clin Gastroenterol 2013; 47(5): 437-9.
54. Muir AJ, Levy C, Janssen HL, Montano‐Loza AJ, Shiffman ML, Caldwell S, et al. Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease. Hepatology 2019; 69(2): 684-98.
55. Traber PG, Chou H, Zomer E, Hong F, Klyosov A, Fiel M-I, et al. Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PloS One 2013; 8(10): e75361.
Send email to the article author

Add your comments about this article
Your username or Email:


XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Olapour S, Yaghooti H. Metabolic dysfunction-associated fatty liver disease and metabolic-associated steatohepatitis: a review of pathogenesis and potential pharmacological targets. Feyz 2022; 26 (5) :605-616
URL: http://feyz.kaums.ac.ir/article-1-4634-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 26, Issue 5 (Bimonthly 2022) Back to browse issues page
مجله علمی پژوهشی فیض ::: دانشگاه علوم پزشکی کاشان KAUMS Journal ( FEYZ )
Persian site map - English site map - Created in 0.05 seconds with 30 queries by YEKTAWEB 4549